Economic evaluation of new medicines: when safety and efficacy are not enough.
Pedersen
Kjeld Moller
KM
Institute of Public Health, University of Southern Denmark, Odense, Denmark.
D000286:Administration, Sublingual; D002986:Clinical Trials as Topic; D003233:Conjunctivitis, Allergic / Q000191:economics* / Q000276:immunology / Q000628:therapy; D003362:Cost-Benefit Analysis / Q000379:methods; D003888:Desensitization, Immunologic / Q000191:economics* / Q000379:methods; D005060:Europe / Q000453:epidemiology; D006801:Humans; D031784:Phleum / Q000276:immunology; D011788:Quality of Life; D006255:Rhinitis, Allergic, Seasonal / Q000191:economics* / Q000276:immunology / Q000628:therapy; D013607:Tablets
D013607:Tablets